Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-lipoic acid for redifferentiation in thyroid cancer
NCT01396733Phase 2
Key facts
- Status
- Withdrawn
- Start
- Apr 2011
- Primary completion
- Dec 2012
- Countries
- 1
- Sponsor
- Asan Medical Center
- Modality
- Small Molecules
- Drugs
- alpha-lipoic acid
- Conditions
- thyroid cancer
01
Overview
Phase 2, randomised, open-label trial of alpha-lipoic acid in thyroid cancer, sponsored by Asan Medical Center. Primary endpoint: Increment of radioactive iodine uptake at 3 months. Planned start Apr 2011; status: withdrawn.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients aged 20-75 with recurrent or metastatic thyroid cancer showing decreased radioactive iodine uptake, excluding those with severe organ failure or specific medication history.
04
Endpoints
Primary
Increment of radioactive iodine uptake
Beyond the preview
Go deeper on NCT01396733.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396733.